October 28, 2026 — HHS has released a narrow interim policy covering six peptide bulk substances for certain patient-specific compounded prescriptions. It does not make BPC-157 or the other five peptides FDA-approved, and it does not cover combination peptide products or every route and formulation.
What does the HHS peptide policy actually do?
HHS says it does not intend to take enforcement action, while final 503A bulks-list rulemaking continues, against a state-licensed pharmacy, federal facility, or licensed physician that compounds one of the six listed peptides and meets every condition in the policy. That is a limited enforcement-discretion policy, not a broad retail opening.
The policy is built around Section 503A, the federal pharmacy-compounding provision for identified patients with valid prescriptions. The statute describes the patient-specific prescription and registered-manufacturer requirements that sit behind this framework. Section 503A pharmacy compounding law explains those baseline rules.
HHS says the policy is intended to discourage certain research-use-only peptides supplied by foreign manufacturers and provide a more controlled alternative under its stated conditions.
Which six peptides are on the interim list?
Appendix A of the HHS interim peptide policy lists BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500.
| Peptide | Route limits in Appendix B |
|---|---|
| BPC-157 | Subcutaneous, intramuscular, oral, or topical |
| TB-500 | Subcutaneous or intramuscular injection |
| MOTS-c | Subcutaneous or intramuscular injection |
| Epitalon | Subcutaneous or intramuscular injection in intermittent courses |
| Semax | Intranasal only |
| KPV | Topical or oral only |
The identity matters as much as the peptide name. HHS ties the policy to the exact substance identity and route described in Appendix B, so a product outside those terms is not covered simply because its label uses one of these names.
Has the FDA approved BPC-157 or these other peptides?
No. HHS states that compounded drugs are not FDA-approved, meaning FDA does not review their safety, effectiveness, or quality before marketing. The policy creates a limited path for qualifying 503A compounding; it is not FDA approval for BPC-157, Epitalon, KPV, MOTS-c, Semax, or TB-500.
That distinction matters when an ad uses the word “approved.” A patient-specific compounded product may fall within this policy only if the pharmacy, prescription, source material, product design, route, reporting, labeling, and other conditions all line up. FDA’s existing 503A interim-compounding guidance also describes the agency’s broader interim framework while the bulks list is developed.
What must a pharmacy do to fit the policy?
HHS sets a detailed set of safeguards. A qualifying compounded product needs a valid patient-specific prescription and must use one listed peptide at the precise identity and route allowed in Appendix B.
| Requirement | What it means for you |
|---|---|
| Documented source material | The original API manufacturer must be FDA-registered under section 510, comply with CGMP requirements, and provide a valid certificate of analysis. |
| Single API | The compounded product may contain only a single active pharmaceutical ingredient listed in Appendix A. |
| Safety and quality reporting | Serious adverse events and product-quality issues must be reported to FDA MedWatch and relevant states. |
| Required label | The label must state: “This is a compounded drug product. Not for resale.” |
| Oral formulations | For an oral dosage form, the policy says the compounder is expected to maintain documentation confirming that the specific formulation achieves adequate oral bioavailability in humans. |
| Delivery device | The only permitted co-packaged or containing device is an FDA 510(k)-cleared syringe. |
HHS also says the policy may be revisited if a safety signal or product-quality issue arises. The agency’s current bulk-substance safety-risk page explains why FDA has focused on peptide characterization, impurities, and immune-reaction concerns during its category reviews.
Are research-use-only peptides covered?
The policy’s enforcement discretion is limited to specified compounding by a state-licensed pharmacy, federal facility, or licensed physician that meets all of its conditions. Outside the policy are combination vials containing two or more peptides, GHK-Cu, and peptides not named in Appendix A. A product must meet every policy condition, including the specified substance identity and route, to fall within the policy’s enforcement-discretion scope.
The policy describes a limited path for qualifying 503A compounding; it does not replace FDA approval or remove the policy’s prescription, sourcing, and product conditions. The first path is not a shortcut around the policy’s prescription, sourcing, and product limits.
Why are these peptides back in the policy debate?
HHS says each of the six was in FDA’s Category 2 from September 2023 until April 22, 2026. In Appendix B, HHS says CDER recommended against listing the substances while the Pharmacy Compounding Advisory Committee voted in favor of inclusion. The policy uses interim enforcement discretion while final rulemaking decides whether each substance is included on the 503A bulks list.
ABC News reported that the July advisory vote was nonbinding. For a wider look at federal health-policy timelines, see Trump women’s health policy.
When does the policy take effect?
The HHS document does not carry a publication or effective date. An October 30, 2026, Federal Register publication has been reported, but that date is reported rather than confirmed in the document. The Office of Information and Regulatory Affairs record for RIN 0910-ZD94 says White House review concluded October 27, 2026, with a decision of “Consistent with Change”; its publication-date field was blank on October 28.
Readers tracking how an administration proposal moves from review to a public record can also compare the step-by-step federal-policy framing in Trump manufacturing policy.
What are critics saying about the policy?
The Partnership for Safe Medicines says it filed a citizen petition on October 16 asking FDA not to allow compounding of peptides it identifies as BPC-157, KPV, TB-500, MOTS-c, emideltide, and Semax. That petition list differs from HHS’s released six-peptide list, which includes Epitalon and does not include emideltide. PSM argues that wider compounding would create public-safety concerns and points to its account of purchases from telehealth services.
The policy includes source, certificate-of-analysis, single-API, route, reporting, and labeling conditions; HHS says those safeguards are part of its limited enforcement-discretion approach.
Before you act on a peptide offer
- Ask whether the exact peptide, identity, route, and dosage form fit Appendix B.
- Confirm that a licensed prescriber issued a patient-specific prescription and that the pharmacy is operating as a qualifying 503A compounder.
- Ask for the product label and how the pharmacy handles required adverse-event and quality reporting.
- Do not treat a multi-peptide blend or an unlisted peptide as covered by this policy.
- If an offer says “FDA-approved,” distinguish an FDA-approved drug from a compounded product covered only by interim enforcement discretion.
By USPatriotNews.com Editorial Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.
